中草藥與新藥研發
237
͉ণਗ਼Չᓥɝɨۜdբ߮eఫdϞ
ݭ
fՉ
ݭ
މ
Όࣺ
Ϟ
ݭ
d࣬
ݭ
༰ɽf༹͚˴
ط
ऊ໕ഐf͏ග͜Չ
ط
ᐕᐖ
सfҢ
ࡁ
༹͚ʕʱᕎ̈
ݺ
ϓʱɚ
萜
◐ᗳ
kansuiphorin A
ձ
B
ྡɖfਗ
ي
ྼ᜕ᜑͪd
kansuiphorin A
ձ
B
ՈϞᜑ
ഹҤͣАषʘ
ݺ
dՉўඎ
ޟ
Эd
ڜ
ᖟəਗ਼Չϓ̌ක೯
ϓᑗґ༊᜕͜ᖹ
ي
ʘዚึf
ක೯ʕণᖹ
א
ʕᖹ˙ኒ˸ϓତБГ˙ᔼᖹٙႾп
ᐕ
ج
வ݊͟ʕෂ୕ᔼኪၾГᔼٙፄΥ˸ᄣ̋Гᖹٙᐕ
ࣖd
א
݊ࠥЭՉ
ݭ
Ը௴อᖹ
ي
ʘഄଫfίԴ͜Гᖹٙᐕ
ج
ʕ̋ɝʕণᖹ
א
ʕᖹ˙ኒdΎ൙П̴݊щ࿁ГᖹϞᄣࣖ
ಯ
ݭ
ٙࣖ
؈
f࿁Ϥɓ˙
ࠃהج
͛̈Ըٙʕণᖹ
א
Չ˙ኒd
ޟ
ЇՉ૿Υʘε၇Ϟࣖϓʱdɰ̙˸Ցอଡ଼ϓၾ
อ͜ɪʘਖ਼л
ڭ
ᚐfΝࣛவɓ
ࡈ
ʕᖹၾГᖹഐΥٙ
˙
ج
dɰˢ༰࢙Ց
FDA
א
Չ˼ᗫዚίʕণᖹ
א
Չ
˙ኒί௴อᏐ͜ɪʘҭ
ࡘ
fɨাʘ
PG-2
ၾරᨾಷ̙
މ
Է
ᗇf
1.
PG-2
ग़༵͉ণɪۜϞɓբᖹdරॾf̴݊ʕᖹʕ
ं௰λٙᖹҿfϞΤٙʕूंಷďঐʕू
ंdʺජᑘfϤ˙͟රॾeɛਞe͚ণeᓥeዒͤe
ʺ௦eࣵ
ߡ
e͈ͣe͛ᑞeɽಈ
ה
ଡ଼ϓdϾරॾу݊Ϥ
ɓ˙ኒʕʘ˴ᖹf
1990
ϋ
ڋ
dҢί
ߕ
̋ψ
Pharmagenesis
